Centers | ||
|
|
|
EU-OPENSCREEN | Chemical Genomics Facility at Purdue Institute for Drug Discovery | Therapeutic Accelerator Program (TAP) |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
The Chemical Genomics Facility is a core facility at Purdue Institute for Drug Discovery that provides expertise and resources needed in the early stage of drug discovery. The services include small molecule libraries, access to automated equipment... Read more |
Test |
Partnerships |
Events |
Jobs |
Research Collaboration and license agreementThe Drug Discovery Unit announces a partnership with Takeda, Japan’s largest pharmaceutical company, to develop possible new therapeutic treatments for tau pathology, an underlying feature in several forms of neurodegeneration, including... View all Janssen Partners with Evotec-Harvard Diabetes Collaboration ProgramJanssen Pharmaceutical a division of Johnson & Johnson has entered into partnership with Harvard University - Evotec's Diabetes program called CureBeta. Janssen will paying $300million in milestone payments per product in addition to $8million in... View all Merck Serono and Feinstein Institute to Develop New Drugs to Treat LupusMerck Serono and Feinstein Institute the research arm of North Shore-Long Island Jewish Health System in New York have entered into a joint collaboration to develop new antibody based therapies to treat Systemic Lupus Erythematosus (SLE). Merck... View all |
No EVENTS for listing |
No Job Posts |
